STOCK TITAN
  1. Home
  2. News
  3. VERA

Vera Therapeutics, Inc. - VERA STOCK NEWS

Welcome to our dedicated page for Vera Therapeutics news (Ticker: VERA), a resource for investors and traders seeking the latest updates and insights on Vera Therapeutics stock.

Vera Therapeutics, Inc. (Nasdaq: VERA) is a late clinical-stage biotechnology company committed to developing and commercializing pioneering treatments for patients with serious immunological diseases. The company's primary product candidate, atacicept, is a fusion protein designed for subcutaneous injection once weekly. Atacicept blocks both B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), thereby inhibiting the stimulation of B cells and plasma cells that produce autoantibodies contributing to autoimmune diseases such as IgA nephropathy (IgAN) and lupus nephritis.

One of the company's significant achievements is the development of atacicept, which has shown promising results in clinical trials. The Phase 2b ORIGIN clinical trial demonstrated atacicept's potential to modify disease progression in IgAN patients, with data showing consistent and sustained reductions in Gd-IgA1, hematuria, and UPCR, along with stable eGFR over 72 weeks. The ongoing pivotal Phase 3 ORIGIN 3 trial aims to further evaluate atacicept's efficacy and safety in a larger cohort of IgAN patients.

Additionally, Vera is advancing MAU868, a monoclonal antibody designed to neutralize BK virus (BKV) infections, which are particularly problematic in kidney transplant patients. Vera retains global developmental and commercial rights to both atacicept and MAU868, positioning the company well in the biopharmaceutical market.

Financially, Vera reported a net loss of $28.4 million for the quarter ended March 31, 2024, with sufficient cash reserves to fund operations through the potential approval and U.S. launch of atacicept. The company has also announced various strategic partnerships and funding rounds to support its ambitious research and development goals.

Recently, Vera Therapeutics received FDA Breakthrough Therapy Designation for atacicept in IgAN, indicating the drug's potential to substantially improve kidney function compared to existing therapies. This designation expedites the development and review process, bringing hope to patients suffering from this debilitating disease.

For more information about Vera Therapeutics and its clinical trials, please visit the company's website at www.veratx.com.

News

Vera Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Rhea-AI Summary
Vera Therapeutics, Inc. (VERA) will participate in the 6th Annual Guggenheim Biotechnology Conference in New York on February 7th and 8th. The management team will engage in a fireside chat and be available for one-on-one investor meetings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.03%
Tags
conferences
-
News

Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Class A Common Stock

Rhea-AI Summary
Vera Therapeutics, Inc. has successfully closed its underwritten public offering of 9,274,194 shares of its Class A common stock, raising approximately $287.5 million. J.P. Morgan, TD Cowen, and Evercore ISI acted as joint book-running managers for the offering, with LifeSci Capital as the lead manager. The offering was made pursuant to a shelf registration statement on Form S-3, including a base prospectus, that was previously filed with the SEC. The press release emphasizes the final prospectus supplement and accompanying prospectus relating to the offering, which are available for free on the SEC’s website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.03%
Tags
offering
-
News

Vera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock

Rhea-AI Summary
Vera Therapeutics, Inc. announced the pricing of an upsized underwritten public offering of 8,064,517 shares of its Class A common stock at $31.00 per share, expected to generate approximately $250.0 million in gross proceeds. The offering is expected to close on February 1, 2024, and has the potential for additional shares to be purchased by underwriters. The proposed offering is being made pursuant to a shelf registration statement on Form S-3 and a related registration statement on Form S-3MEF.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.59%
Tags
offering
News

Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock

Rhea-AI Summary
Vera Therapeutics, Inc. plans to commence a public offering to issue and sell $200.0 million of shares of its Class A common stock. The underwriters will have a 30-day option to purchase up to an additional 15% of the shares. The proposed offering is being made pursuant to a shelf registration statement on Form S-3. J.P. Morgan, TD Cowen, and Evercore ISI are acting as joint book-running managers for the proposed offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.46%
Tags
offering
-
News

Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy

Rhea-AI Summary
Vera Therapeutics, Inc. (Nasdaq: VERA) announced positive 72-week data from the open label extension (OLE) period of its Phase 2b ORIGIN clinical trial of atacicept in participants with IgA nephropathy (IgAN), showing consistent and sustained reductions in Gd-lgA1, hematuria, and UPCR, with stable eGFR over the duration of treatment. Participants treated with atacicept for 72 weeks demonstrated a 62% reduction in Gd-IgA1, a reduction in the percentage of participants with hematuria to 19%, and a 48% reduction in UPCR in the per-protocol (PP) analysis. Safety data indicated that atacicept was generally well-tolerated.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
48.71%
Tags
clinical trial
-
News

Vera Therapeutics Announces Appointment of Industry Veterans Robert Brenner, M.D. as Chief Medical Officer and William D. Turner as Chief Development Officer

Rhea-AI Summary
Vera Therapeutics, Inc. (Nasdaq: VERA) announces the appointment of two industry veterans to lead the development of the company’s drug programs, including its late-stage product candidate, atacicept, currently in a Phase 3 clinical trial for IgA nephropathy (IgAN). Dr. Robert M. Brenner, a respected nephrologist and biotechnology executive, is appointed as Chief Medical Officer, while Mr. William D. Turner, with nearly 30 years of drug development and commercialization experience, is appointed as Chief Development Officer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.74%
Tags
management
News

Vera Therapeutics to Host In-Person R&D Day in New York to Present Week 72 Data from Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN on January 25, 2024

Rhea-AI Summary
Vera Therapeutics, Inc. (Nasdaq: VERA) to Host R&D Day with Phase 2b Clinical Trial Data Presentation for Atacicept on January 25, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.74%
Tags
conferences clinical trial
-
News

Vera Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary
Vera Therapeutics, Inc. (Nasdaq: VERA) will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA from January 7 – 11, 2024. The management team will also participate in one-on-one investor meetings. The presentation will be on Tuesday, January 9th at 3:00 PM PST and can be accessed via webcast. A replay of the event will be available for 90 days on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.31%
Tags
conferences
-
News

Vera Therapeutics Provides Business Update and Reports Third Quarter Financial Results

Rhea-AI Summary
Vera Therapeutics, Inc. (Nasdaq: VERA) reported positive data from the Phase 2b ORIGIN trial at Kidney Week 2023, supporting the potential of atacicept as a treatment for IgA nephropathy (IgAN). The company also presented strong financial results and a robust balance sheet, with upcoming milestones including the presentation of Phase 2b open-label extension data in Q1 2024 and full enrollment of Phase 3 ORIGIN 3 trial in H2 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.09%
Tags
earnings
News

Vera Therapeutics Presents Positive Data from Phase 2b ORIGIN Study Showing Resolution of Hematuria in Majority of Patients at the American Society of Nephrology Kidney Week 2023

Rhea-AI Summary
Vera Therapeutics announces positive results from the Phase 2b ORIGIN study of atacicept in patients with immunoglobulin A nephropathy (IgAN). Hematuria resolved in 80% of patients receiving atacicept compared to 5% in the placebo group. High serum levels of Gd-IgA1 were significantly reduced in patients on atacicept. The company is on track with enrollment for the Phase 3 ORIGIN 3 trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial

FAQ

What is the current stock price of Vera Therapeutics (VERA)?

The current stock price of Vera Therapeutics (VERA) is $47.03 as of November 21, 2024.

What is the market cap of Vera Therapeutics (VERA)?

The market cap of Vera Therapeutics (VERA) is approximately 3.0B.

What is Vera Therapeutics?

Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases.

What is atacicept?

Atacicept is a fusion protein developed by Vera Therapeutics for the treatment of autoimmune diseases, administered as a subcutaneous injection once weekly.

What is the ORIGIN clinical trial?

The ORIGIN clinical trial is a series of studies evaluating the safety and efficacy of atacicept in patients with IgA nephropathy (IgAN).

What is IgA nephropathy (IgAN)?

IgAN, also known as Berger’s disease, is a serious autoimmune disease of the kidney characterized by the production of immunogenic Gd-IgA1 and progressive kidney damage.

What is MAU868?

MAU868 is a monoclonal antibody developed by Vera Therapeutics to neutralize BK virus (BKV) infections, particularly in kidney transplant patients.

What recent achievements has Vera Therapeutics reported?

Vera recently announced positive 72-week data from its Phase 2b ORIGIN trial of atacicept in IgAN and received FDA Breakthrough Therapy Designation for atacicept.

How is atacicept administered?

Atacicept is administered as a subcutaneous injection once weekly.

What are the financial highlights of Vera Therapeutics?

For the quarter ended March 31, 2024, Vera reported a net loss of $28.4 million, with cash reserves to fund operations through the approval and U.S. launch of atacicept.

Who are Vera’s strategic partners?

Vera has various strategic partnerships and funding rounds to support its research and development, including J.P. Morgan, TD Cowen, and Evercore ISI.

Where can I find more information about Vera Therapeutics?

For more information, please visit the company's website at www.veratx.com.

Stock VERA logo
Vera Therapeutics, Inc.

Nasdaq:VERA

VERA Rankings

#1697 Ranked by Market Cap
N/A Ranked by Dividends

VERA Stock Data

2.97B
58.33M
6.74%
94.71%
10.31%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
BRISBANE